期刊文献+

胃肠B细胞非霍奇金淋巴瘤病理特征及预后分析 被引量:3

An Correlation Analysis on Clinical Pathological Features and Prognosis of Gastrointestinal B Cell Lymphomas
下载PDF
导出
摘要 目的:观察胃肠B细胞性非霍奇金淋巴瘤的临床病理特征,Bcl-2、ki-67、CD5的表达和幽门螺杆菌(Hp)的感染对其临床病理特征及预后的影响。方法:收集18例病人的临床病理资料并进行随访,通过HE及免疫组织化学染色,观察黏膜相关淋巴瘤及氵弥漫大B细胞淋巴瘤的组织学特点,检测Bcl-2、ki-67、CD5及Hp,对所得资料进行统计学分析。结果:CD5、ki-67表达及Hp感染均随着临床分期的增加而增加。Bcl-2阳性组及ki-67表达>30%组的淋巴结累及率要高于Bcl-2阴性组及ki-67表达≤30%组。CD5阳性组的生存状况要好于阴性组,而ki-67表达>30%组及Hp感染组生存状况要差于ki-67表达≤30%组及Hp未感染组。结论:Bcl-2、CD5表达、ki-67高表达及Hp感染可能与晚期淋巴瘤有关,Bcl-2表达、ki-67高表达可能与淋巴结受累有关,而ki-67表达、Hp感染与较差的生存状况相关。 Objective: To observe the clinicopathogical features expression of Bcl-2, CDS, Ki-67 and the influence of Helicobacter of gastrointestinal B cell lymphomas, pylori(Hp) infection to chnicopathogical features and prognosis of patients. Methods: The clinicopathogical data of 18 patients were collected and further follow-up was carried out. The expression of Bcl-2, CD5, Ki-67 and Hp infection were checked by using immunohistochemistry method. All of the data were statistically analyzed. Resuits: The expression of CD5, and Ki-67, and Hp infection rates increased along with the increasing of the clinical staging of the disease. The rates of lymph node involvement in the groups of Bcl-2-positive and Ki-67 higher ( 〉30% ) expression (66.67% and 77.78% ) were higher than those in groups of Bcl-2-negative and Ki-67 lower ( ≤30% ) expression (33.33% and 22.22% ). The survival rate of CD5-positive group ( 100% ) was higher than that of CD5-negative group (50%), while the survival rates in groups of Ki-67 higher expression and Hp infection-positive (66.67% and 33.33% ) were lower than those in groups of Ki-67 lower expression and Hp infection-negative ( 100% and 83.33% ). Conclusion: The advanced stage of the disease seems accompanied by expression of CD5, higher expression of Ki-67 and Hp infection. Lymph node involvement associates with Bcl-2 expression and higher expression of Ki-67. Lower survival rates associate with higher expression of Ki-67 and Hp infection.
出处 《贵阳医学院学报》 CAS 2008年第2期125-128,131,共5页 Journal of Guiyang Medical College
基金 贵州省长基金资助项目(S2004-18) 贵州省卫生厅科技计划项目(G2005-2)
关键词 淋巴瘤 非霍奇金 淋巴瘤 B细胞 胃肠肿瘤 基因 Bcl-2 KI-67抗原 抗原 CD5 预后 lymphoma, non-Hodgkin lymphoma, B-cell gastrointestinal neoplasms genes, bcl-2 ki-67 antigen antigens, CDS prognosis
  • 相关文献

参考文献11

  • 1Hioka T, Miura I, Kume M, et al. Cytogenetic features of de novo CDS-positive diffuse large B-cell lymphoma [ J ]. Genes Chromosomes Cancer,2005(2) : 149 - 157.
  • 2克晓燕,景红梅,李敏,安秀云,高子芬.37例黏膜相关淋巴组织型淋巴瘤的病理、临床资料分析[J].北京大学学报(医学版),2003,35(2):123-127. 被引量:11
  • 3Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach: A review of treatment option[ J ]. Int J Radiation Oncol Phys, 2000 (46) : 1093 - 1103.
  • 4Reena Ray, Gao Chen, Christine Vande Velde, et al. BNIP3 heterodimerizes with Bcl-2/Bcl-x1 and induces cell death independent of Bcl-2 homology3 ( BH3 ) domain at both mitochondrial and nonmitochondrial sites [ J ], J Biol Chem, 2000(2) :1439 - 1448.
  • 5吕方芳,陆洪芬,印季良,施达仁,范月珍,李进,洪小南.survivin、bcl-2及ki-67在弥漫大B细胞淋巴瘤中的表达及临床意义[J].肿瘤,2006,26(10):930-934. 被引量:7
  • 6Yoshioka T, Miura I, Kume M, et al. Cytogenetic features of de novo CDS-positive diffuse large B-cell lymphoma [ J ]. Genes Chromosomes Cancer,2005 (2): 149 - 157.
  • 7Suguro M ,Tagawa H,Kagami Y, et al. Expression profiling analysis of the CD5 + diffuse large B-cell lymphoma subgroup: development of a CD5 signature [ J ]. Cancer Sci,2006(9) :868 -874.
  • 8Nakamura S, Matsumato T. Chromosomal translocation t ( 11 ; 18 ) ( q21 ; q21 ) in gastrointestinal mucosa associated lymphoid tissue lymphoma [ J ]. J Clin Patho1,2003 (56) : 36 - 42.
  • 9Ye H T, Liu H X, Attygalle A, et al. Variable frequencies of t( 11 ; 18) (q21 ;q21 ) in MALT lymphoma of different sites: significant association with CagA strain of H pylofi in gastric MALT lymphoma [J]. Blood, 2003 (3) : 1012 - 1018.
  • 10尹洪芳,李挺,张莹.胃肠B细胞淋巴瘤的增殖与凋亡及其与幽门螺杆菌的关系[J].北京大学学报(医学版),2004,36(4):348-352. 被引量:4

二级参考文献43

  • 1Hayes J, Dunn E. Has the incidence of primary gastric lymphoma increased [J] ? Cancer, 1989, 63: 2073 - 2076
  • 2Severson RK, Davis S. Increasing incidence of primary gastric lymphoma[J]. Cancer, 1990, 66:183-187
  • 3Gisbertz IAM, Schouten HC, Bot F J, et al. Proliferation and apoptosis in primary gastric B-cell non-Hodgkin's lymphoma[J]. Histopathology, 1997, 30:152 - 159
  • 4Eidt S, Stoite M, Fischer R. Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas[J]. J Clin Pathol, 1994, 47:436 - 439
  • 5Xu WS, Ho FCS, HO J, et al. Pathogenesis of gastric lymphoma:the enigma in Hong Kong[J]. Ann Oncol, 1997, 8 ( Suppl 2): S41-S44
  • 6Raderer M, Pfeffel F, Pohl G, et al. Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori[J]. Gut, 2000, 46: 133 - 135
  • 7Isaacson PG, Muller-Hermelink HK, Piris MA. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue ( MALT lymphoma)[A]. In: Jaffe ES, Harris NL, Stein H, eds: World Health Organization Classification of Tumours. Pathology and Geneti
  • 8Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92 [J]. J Clin Oncol,
  • 9Nakamura S, Matsumoto T, Iida M, et al. Primary gastrointestinal lymphoma in Japan. A clinicopathologic Analysis of 455 patients with special reference to its time trends[J]. Cancer, 2003, 97:2462 -2473
  • 10Nakamura S, Yao T, Aoyagi K, et al. Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients[J]. Cancer, 1997, 79: 3 - 11

共引文献25

同被引文献34

  • 1王旦,黄磊,吴建胜,吴明,黄智铭,陈民新.CT联合内镜检查对胃肠道恶性淋巴瘤的诊断价值[J].中国内镜杂志,2007,13(2):182-185. 被引量:10
  • 2Yun J,Kim SJ,Kim JA,et al.Clinical features and treatment outcomes of non-Hodgkin′s lymphomas involving rare extranodal sites:a single-center experience[J].Acta Haematol,2010,123(1):48.
  • 3Zwick C,Gleissner B,Pfreundschuh M.Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma[J].Clin Lymphoma Myeloma,2007,8(Suppl 2):S43.
  • 4Wilson WH,Gutierrez M,O′Connor P,et al.The role of rituximab and chemotherapy in aggressive B-cell lymphoma:a preliminary report of dose-adjusted EPOCH-R[J].Semin Oncol,2002,29(1 Suppl 2):41.
  • 5Kewalramani T,Zelenetz AD,Nimer SD,et al.Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma[J].Blood,2004,103(10):3684.
  • 6贺降福,刘荣,胡仕林,沈俊松,王银,陈新皓.胃黏膜相关淋巴组织淋巴瘤临床与内镜诊断分析[J].国际消化病杂志,2007,27(4):306-308. 被引量:6
  • 7Kuo JR,Hou YY,Chu ST,et al.Subglottic stenosis induced by extranodal mucosa-associated lymphoid tissue lymphoma[J].J Chin Med Assoc,2011,74(3):144.
  • 8Thomas L C,Maida M J,Martinez-Outschoorn U,et al.Chronic lymphocytic leukemia/small lymphocytic lymphoma with pancytopenia and chylothorax[J].Semin Oncol,2011,38(2):165.
  • 9Howman R A,Prince H M.New drug therapies in peripheral T-cell lymphoma[J].Expert Rev Anticancer Ther,2011,11(3):457.
  • 10Halwani A S,Link B K.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin' s lymphoma[J].Expert Rev Anticancer Ther,2011,11 (3):443.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部